Dow (NYSE:DOW) subsidiary Dow Corning presented its latest drug delivery tech for transdermal therapies at the American Assn. of Pharmaceutical Sciences annual meeting.
Dow Corning introduced its transdermal delivery patch, the SilAc Hybrid pressure-sensitive adhesive, which combine the properties of acrylic and silicone polymers. The Midland, Mich.-based company also featured its silicone-based topical ingredients with enhanced spreading capabilities and sensory properties so its customers can develop novel formulations for acne management.
“Transdermal and topical drug delivery systems must ensure proper drug loading, stability and release,” strategic marketing director for healthcare Gary Lord said in prepared remarks. “Dow Corning supports evolving industry requirements by continuing to expand our silicone-based solutions for drug delivery and consumer healthcare applications. We have enhanced our BIO-PSA family with a single-technology hybrid solution that addresses multiple needs for patch formulators and pharmaceutical companies. Also, we are offering formulators new concepts for the growing market in OTC acne management. Through innovation and collaboration, Dow Corning is helping the industry achieve its current and future goals.”
Dow Pharma Solutions showcased a number of compounds designed to enhance solubility and productivity of pharmaceuticals, such as the Ethocel High Productivity polymers used for high-speed dry powder layering processes and the Methocel DC2 for dry powder processing.
For 73 years, Dow Corning was a joint venture between Dow and Corning. In June 2016, Dow became 100% owner of Dow Corning’s silicones business.
“Separately, Dow and Dow Corning were experts in drug delivery, but coming together truly deepens, broadens and strengthens our expertise,” Dow Pharma Solutions global marketing leader Dago Caceres added. “Strong synergies between our 2 organizations provide access to expanded resources, services and technologies, including additional research and development capabilities.”
